Bon Natural Life (BON) Competitors $1.12 +0.01 (+0.72%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.12 +0.00 (+0.18%) As of 02/21/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends BON vs. APM, VRAX, CMND, SNGX, ONVO, ABVC, ALZN, FRTX, MAAQ, and CANFShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Aptorum Group (APM), Virax Biolabs Group (VRAX), Clearmind Medicine (CMND), Soligenix (SNGX), Organovo (ONVO), ABVC BioPharma (ABVC), Alzamend Neuro (ALZN), Fresh Tracks Therapeutics (FRTX), Mana Capital Acquisition (MAAQ), and Can-Fite BioPharma (CANF). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Aptorum Group Virax Biolabs Group Clearmind Medicine Soligenix Organovo ABVC BioPharma Alzamend Neuro Fresh Tracks Therapeutics Mana Capital Acquisition Can-Fite BioPharma Aptorum Group (NASDAQ:APM) and Bon Natural Life (NYSE:BON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Do institutionals and insiders believe in APM or BON? 3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor APM or BON? Aptorum Group received 41 more outperform votes than Bon Natural Life when rated by MarketBeat users. CompanyUnderperformOutperformAptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Bon Natural LifeN/AN/A Which has stronger earnings and valuation, APM or BON? Bon Natural Life has higher revenue and earnings than Aptorum Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptorum Group$430K13.19-$2.83MN/AN/ABon Natural Life$23.84M0.06$400KN/AN/A Is APM or BON more profitable? Company Net Margins Return on Equity Return on Assets Aptorum GroupN/A N/A N/A Bon Natural Life N/A N/A N/A Does the media refer more to APM or BON? In the previous week, Aptorum Group's average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score. Company Overall Sentiment Aptorum Group Neutral Bon Natural Life Neutral Which has more risk & volatility, APM or BON? Aptorum Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500. SummaryAptorum Group beats Bon Natural Life on 5 of the 7 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$1.31M$1.16B$8.49B$20.30BDividend YieldN/AN/A2.80%3.64%P/E RatioN/A35.7814.6834.91Price / Sales0.065.726.9717.22Price / Cash0.7810.4030.8420.26Price / Book0.031.924.634.80Net Income$400,000.00-$53.22M$259.02M$1.02B7 Day Performance-14.92%-5.53%-2.90%-1.07%1 Month Performance-18.40%-1.92%-0.44%-1.11%1 Year Performance-77.32%-13.79%6.14%13.69% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.12+0.7%N/A-78.7%$1.31M$23.84M0.00100APMAptorum Group0.4972 of 5 stars$1.19-0.8%N/A-38.1%$6.16M$430,000.000.0030Gap UpVRAXVirax Biolabs Group0.8384 of 5 stars$1.90+1.3%N/A+93.9%$6.15M$160,000.000.005CMNDClearmind MedicineN/A$1.41+0.7%N/A-27.9%$6.02MN/A-0.75N/AGap UpSNGXSoligenix1.1949 of 5 stars$2.39-2.8%N/A-79.1%$6.00M$840,000.00-0.3220News CoverageONVOOrganovo1.1127 of 5 stars$0.39+2.1%N/A-63.1%$5.93M$110,000.00-0.3620Earnings ReportABVCABVC BioPharma1.1199 of 5 stars$0.46+8.9%N/A-41.2%$5.93M$150,000.00-0.5330News CoveragePositive NewsGap DownHigh Trading VolumeALZNAlzamend Neuro2.6121 of 5 stars$1.09+0.9%$32.00+2,835.8%-88.9%$5.92MN/A0.004Gap UpFRTXFresh Tracks TherapeuticsN/A$0.93-0.3%N/A-1.1%$5.55M$8.01M-0.6620MAAQMana Capital AcquisitionN/A$0.67-1.2%N/A-72.6%$5.44MN/A0.001High Trading VolumeCANFCan-Fite BioPharma1.9168 of 5 stars$1.53+1.0%$14.00+818.0%-11.7%$5.40M$740,000.00-0.858Analyst Forecast Related Companies and Tools Related Companies Aptorum Group Competitors Virax Biolabs Group Competitors Clearmind Medicine Competitors Soligenix Competitors Organovo Competitors ABVC BioPharma Competitors Alzamend Neuro Competitors Fresh Tracks Therapeutics Competitors Mana Capital Acquisition Competitors Can-Fite BioPharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:BON) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredThis quote from Elon says it all… (AI Breakthrough)MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BON Stock Alerts